Policy UpdatesMedicaidJanuary 30, 2025

Clinical Criteria updates

Effective May 8, 2025

Summary: The Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.

Please see the explanation/definition for each category of Clinical Criteria below:

  • New: newly published criteria
  • Revised: addition or removal of medical necessity requirements, new document number

Please share this notice with other members of your practice and office staff.

Please note:

  • The Clinical Criteria listed below apply only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
  • This notice is meant to inform the provider of new or revised criteria that have been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective Date

Clinical Criteria Number

Clinical Criteria Title

New or Revised

May 8, 2025

CC-0267

Ebglyss (lebrikizumab-lbkz)

New

May 8, 2025

CC-0268

Lymphir (denileukin diftitox-cxdl)

New

May 8, 2025

CC-0269

Nemluvio (nemolizumab-ilto)

New

May 8, 2025

CC-0270

Niktimvo (axatilmab-csfr)

New

May 8, 2025

CC-0271

Tecelra (afamitresgene autoleucel)

New

May 8, 2025

CC-0012

Brineura (cerliponase alfa)

Revised

May 8, 2025

CC-0250

Veopoz (pozelimab-bbfg)

Revised

May 8, 2025

CC-0072

Vascular Endothelial Growth Factor (VEGF) Inhibitors

Revised

May 8, 2025

CC-0029

Dupixent (dupilumab)

Revised

May 8, 2025

CC-0201

Rybrevant (amivantamab-ymjw)

Revised

May 8, 2025

CC-0130

Imfinzi (durvalumab)

Revised

May 8, 2025

CC-0002

Colony Stimulating Factor Agents

Revised

May 8, 2025

CC-0050

Monoclonal Antibodies to Interleukin-23

Revised

May 8, 2025

CC-0011

Ocrevus (ocrelizumab)/Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq)

Revised

Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

CABC-CD-073074-24-CPN72605

PUBLICATIONS: March 2025 Provider Newsletter